Calculating The Intrinsic Value Of Vetoquinol SA (EPA:VETO)
Today we will run through one way of estimating the intrinsic value of Vetoquinol SA ( EPA:VETO ) by estimating the...
Has the French Pharma Industry valuation changed over the past few years?
|Fri, 21 Jan 2022||€127.8b||€43.2b||€7.0b||20.3x|
|Sun, 19 Dec 2021||€121.9b||€43.2b||€7.0b||21.6x|
|Tue, 16 Nov 2021||€127.0b||€43.2b||€7.0b||21.7x|
|Thu, 14 Oct 2021||€117.7b||€42.3b||€6.6b||18.8x|
|Sat, 11 Sep 2021||€114.9b||€42.2b||€6.6b||21.7x|
|Mon, 09 Aug 2021||€122.2b||€42.2b||€6.6b||20.5x|
|Sun, 02 May 2021||€120.3b||€41.6b||€12.9b||16.6x|
|Wed, 03 Feb 2021||€106.8b||€41.9b||€13.0b||13.2x|
|Sat, 07 Nov 2020||€107.1b||€42.2b||€11.6b||20.3x|
|Fri, 31 Jul 2020||€121.1b||€42.3b||€11.2b||18.1x|
|Mon, 04 May 2020||€120.1b||€42.8b||€3.5b||23.8x|
|Thu, 06 Feb 2020||€117.8b||€42.2b||€3.0b||30.1x|
|Sun, 10 Nov 2019||€114.6b||€41.4b||€3.4b||32.6x|
|Sat, 03 Aug 2019||€106.0b||€41.1b||€4.1b||21.2x|
|Tue, 07 May 2019||€108.3b||€40.6b||€4.9b||21.8x|
|Fri, 08 Feb 2019||€105.2b||€39.9b||€4.8b||21.6x|
Current Industry PE: Investors are relatively neutral on the industry at the moment, considering it's trading close to its 3-year average PE ratio of 21.9x. It appears they believe that earnings will grow in-line with historical growth rates.
Past Earnings Growth: The earnings for companies in the Pharmaceuticals industry have grown 13% per year over the last three years, and revenues for these companies have grown 2.7% per year. This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Which industries have driven the changes within the French Pharma industry?
Industry PE: Investors are most optimistic about the Pharma industry, which is trading close to its 3-year average PE ratio of 21.9x. This is likely because analysts are expecting annual earnings growth of 9.4%, which is higher than its past year's earnings decline of 6.6% per year.
Forecasted Growth: Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 9.4% over the next 5 years. This is better than its past earnings decline of 6.6% per year.
Theranexus Société Anonyme